StockNews.AI
AKRO
StockNews.AI
3 hrs

Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025

1. Akero will present at AASLD The Liver Meeting® 2025. 2. Efruxifermin showed potential benefits in compensated cirrhosis patients. 3. AI analysis from HARMONY study reveals positive liver changes. 4. Three Phase 3 clinical studies for efruxifermin ongoing. 5. Findings could strengthen investor confidence in AKRO.

5m saved
Insight
Article

FAQ

Why Bullish?

Successful presentations can boost investor perception and stock value. Historical gains often followed positive clinical trial data for biotech stocks.

How important is it?

Key clinical data presentations and positive trends can significantly influence stock performance.

Why Short Term?

Upcoming presentations in November 2025 may impact stock price quickly. Immediate investor reactions expected post-presentation.

Related Companies

GILDNVSAMGN
October 07, 2025 07:00 ET  | Source: Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two upcoming oral presentations and a poster presentation at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 taking place November 7-11, 2025, in Washington, DC. The presentations will highlight findings from the 96-week Phase 2b SYMMETRY study evaluating the safety and efficacy of lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4c) due to metabolic dysfunction-associated steatohepatitis (MASH), along with insights from an AI-powered digital analysis of histology data from the 96-week Phase 2b HARMONY study in patients with pre-cirrhotic (F2-F3) MASH. Details for the presentations are as follows: Oral Presentations Title: Efruxifermin was associated with improvements in multiple non-invasive tests indicative of fibrosis regression in participants with compensated cirrhosis due to MASH (SYMMETRY)Presenter: Vlad Ratziu, M.D., Ph.D., Professor of Hepatology, Sorbonne Université and the Hôpital Pitié-Salpêtrière Medical SchoolSession: Clinical Plenary #1Date/Time: Sunday, November 9, 2025, 12:00 PM ET Title: Efruxifermin improved markers of portal hypertension as evaluated by Baveno VII criteria in compensated cirrhosis due to MASH: results from a 96-week, placebo-controlled, phase 2b trialPresenter: Mazen Noureddin, M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital and Director, Houston Research InstituteSession: MASH Clinical TrialsDate/Time: Sunday, November 9, 2025, 2:45 PM ET Poster Presentation Title: AI-powered histology analysis of HARMONY reveals Efruxifermin-driven changes in the liver microarchitecture in F2/F3 MASHPresenter: Jörn M. Schattenberg, M.D., Professor of Medicine, Director of the Department of Medicine, Saarland University Medical Center, University of SaarlandSession: MASLD/MASH Therapeutics: New Agents and Approved / Available AgentsDate/Time: Monday, November 10, 2025, from 11:30 AM-12:30 PM ET About Akero Therapeutics Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4c) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information. Investor Contact:Christina TartagliaPrecision AQ212.362.1200IR@akerotx.com Media Contact:Peg RusconiDeerfield Group617.910.6217Peg.rusconi@deerfieldgroup.com

Related News